已收盘 12-19 16:00:00 美东时间
+0.043
+6.83%
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.34) by 61.19 percent. This is a 63.89 percent increase over losses of $(0.36) per share from the
11-14 21:11
Study Meets Overall Response Rate Primary Endpoint, Encouraging Secondary Endpoint Progression-Free Survival Data in Squamous Cell Carcinoma of the Head and Neck Cohort.No New Safety Signals or Added Systemic Safety
2024-09-16 16:42
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 2% on Tuesday. The Dow traded down 1.49% to 40,944.47 while the NASDAQ fell 3.07% to 17,169.68. The S&P 500 also fell, dropping, 2% to 5,535.29. Check This Out: Dow Hits Record High, S&P 500 Gains For 4th Consecutive...
2024-09-04 02:59
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) dipped 11.6% to $6.43. The company on Tuesday announced Phase 2 data for an investigational treatment for symptomatic Cerebral Cavernous Malformation (CCM). Nikola shares dipped 10.4% to $7.28 on Monday. Here are some other stocks moving in tod...
2024-09-04 01:41
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 1% on Tuesday. The Dow traded down 0.94% to 41,173.76 while the NASDAQ fell 2.22% to 17,320.89. The S&P 500 also fell, dropping, 1.28% to 5,575.91. Check This Out: Dow Hits Record High, S&P 500 Gains For 4th Conse...
2024-09-04 00:00
Morgan Stanley analyst Matthew Harrison maintains IO Biotech (NASDAQ:IOBT) with a Overweight and lowers the price target from $7 to $4.
2024-09-03 19:49
Gainers Conduit Pharmaceuticals (NASDAQ:CDT) stock increased by 27.4% to $0.16 during Monday's after-market session. The company's market cap stands at $15.0 million. TNF Pharmaceuticals (NASDAQ:TNFA) stock moved upwards by 18.82% to $2.02. The market value of their outstanding shares is at $4.7 mil...
2024-09-03 04:31
04:34 PM EDT, 08/30/2024 (MT Newswires) -- IO Biotech (IOBT) said Friday that an Independent Data Monitoring Committee has recommended the continuation of its late-stage trial of vaccine candidate IO102-IO103 in combination with Merck's (MRK) Keytruda as a first-line treatment for patients with unre...
2024-08-31 04:34